DALLAS and NEW YORK, Nov. 24,
2014 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc.
announced today that FINRA has approved a change of Company's stock
ticker symbol. Effective today, the Company's common shares
will commence trading on the OTC Bulletin Board under the trading
symbol "PTBI". The previous trading symbol was "ACCPD."
About PlasmaTech Biopharmaceuticals, Inc.: PlasmaTech
Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical
company focused on advancing targeted treatments for significant
unmet needs of critical patient care. Exploiting two distinct
proprietary platforms, Salt Diafiltration (SDF™) Process and
Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the
development and commercialization of plasma-derived therapeutics
and cancer supportive care products. The company has a robust
product pipeline that includes two commercial stage products,
MuGard® and ProctiGard™ and multiple follow-on products in
development. For more information visit www.plasmatechbio.com.
Company and Media Contact:
Christine Berni
Vice President, Corporate Development
PlasmaTech Biopharmaceuticals, Inc.
(212) 786-6208
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/plasmatech-biopharmaceuticals-inc-announces-stock-ticker-symbol-change-to-ptbi-300000047.html
SOURCE PlasmaTech Biopharmaceuticals, Inc.